APA (7th ed.) Citation

Bartl, T., Onoprienko, A., Hofstetter, G., Müllauer, L., Poetsch, N., Fuereder, T., . . . Grimm, C. (2021). Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG.

Chicago Style (17th ed.) Citation

Bartl, Thomas, Arina Onoprienko, Gerda Hofstetter, Leonhard Müllauer, Nina Poetsch, Thorsten Fuereder, Paul Kofler, Stephan Polterauer, and Christoph Grimm. Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG, 2021.

MLA (8th ed.) Citation

Bartl, Thomas, et al. Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG, 2021.